| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Assessment of Effects of Lipid-Lowering Drugs on Hemostasis
|
Altman, Raul
|
|
1998
|
81 |
8S1 |
p. 73F-74F
nvt p.
|
artikel
|
| 2 |
Basic Requirements for Investigational New Drug and New Drug Application Approval for an Antioxidant Compound in Cardiovascular Disease
|
L. Witztum, Joseph
|
|
1998
|
81 |
8S1 |
p. 50F-51F
nvt p.
|
artikel
|
| 3 |
Clinical Trial Assessment of Lipid-Acting Drugs in Diabetic Patients
|
Steiner, George
|
|
1998
|
81 |
8S1 |
p. 58F-59F
nvt p.
|
artikel
|
| 4 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 89F-90F
nvt p.
|
artikel
|
| 5 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 82F-83F
nvt p.
|
artikel
|
| 6 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 92F-94F
nvt p.
|
artikel
|
| 7 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 80F-81F
nvt p.
|
artikel
|
| 8 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 88F-89F
nvt p.
|
artikel
|
| 9 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 90F-92F
nvt p.
|
artikel
|
| 10 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 84F-86F
nvt p.
|
artikel
|
| 11 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 86F-87F
nvt p.
|
artikel
|
| 12 |
Discussion
|
|
|
1998
|
81 |
8S1 |
p. 81F-82F
nvt p.
|
artikel
|
| 13 |
Documentation of Efficacy of Drugs Affecting Apoptosis and Other Atheroma-Related Mechanisms
|
McCormick, Thomas S
|
|
1998
|
81 |
8S1 |
p. 48F-49F
nvt p.
|
artikel
|
| 14 |
Early Efficacy and Safety Studies
|
Sirtori, Cesare R
|
|
1998
|
81 |
8S1 |
p. 13F-16F
nvt p.
|
artikel
|
| 15 |
Editorial
|
|
|
1998
|
81 |
8S1 |
p. 1F-
1 p.
|
artikel
|
| 16 |
Efficacy and Safety in Phase II Trials
|
Black, Donald M.
|
|
1998
|
81 |
8S1 |
p. 25F-26F
nvt p.
|
artikel
|
| 17 |
Evaluation of Lipoproteins/Apolipoproteins as Therapeutic Agents for the Treatment of Vascular and Nonvascular Disease
|
Sirtori, Cesare R
|
|
1998
|
81 |
8S1 |
p. 36F-39F
nvt p.
|
artikel
|
| 18 |
Guidance for Industry: Over-the-Counter Treatment of Hypercholesterolemia
|
Weintraub, Michael
|
|
1998
|
81 |
8S1 |
p. 78F-
1 p.
|
artikel
|
| 19 |
Guidelines for Approval of Anti-obesity Drugs Affecting Atherosclerosis and/or Lipids
|
Anderson, James W.
|
|
1998
|
81 |
8S1 |
p. 29F-30F
nvt p.
|
artikel
|
| 20 |
Guidelines for Methods to Determine Efficacy and Safety of Drugs Acting on the Gastrointestinal Tract
|
Kesäniemi, Y.Antero
|
|
1998
|
81 |
8S1 |
p. 27F-28F
nvt p.
|
artikel
|
| 21 |
Guidelines for Trials of Gene Therapy and Somatic Gene Therapy in Cardiovascular Disease
|
Hoeg, Jeffrey M
|
|
1998
|
81 |
8S1 |
p. 60F-63F
nvt p.
|
artikel
|
| 22 |
Inclusion of Lipoprotein Subfractions Among Efficacy Parameters
|
Superko, H.Robert
|
|
1998
|
81 |
8S1 |
p. 52F-55F
nvt p.
|
artikel
|
| 23 |
Investigational New Drug Applications: The Role of the Preclinical Dossier
|
Paterniti Jr., James R
|
|
1998
|
81 |
8S1 |
p. 10F-12F
nvt p.
|
artikel
|
| 24 |
Methods and Endpoint Issues in Clinical Development of Lipid-Acting Agents with Pleiotropic Effects
|
Davignon, Jean
|
|
1998
|
81 |
8S1 |
p. 17F-24F
nvt p.
|
artikel
|
| 25 |
Phase III and Phase IV Trials: Noninvasive Assessment of Efficacy Endpoints in Vessel Walls
|
Levenson, Jaime
|
|
1998
|
81 |
8S1 |
p. 67F-68F
nvt p.
|
artikel
|
| 26 |
Potential Stifling Effects of Pharmaco-Economics and Regulatory Policies
|
Data, Joann L.
|
|
1998
|
81 |
8S1 |
p. 34F-35F
nvt p.
|
artikel
|
| 27 |
Recommendations for Phase IV Studies in the Development of Lipid-Lowering Drugs
|
Gregg, R.E.
|
|
1998
|
81 |
8S1 |
p. 64F-66F
nvt p.
|
artikel
|
| 28 |
Regulatory Concerns at Various Phases of Drug Development
|
Aurecchia, Steven
|
|
1998
|
81 |
8S1 |
p. 2F-4F
nvt p.
|
artikel
|
| 29 |
Relation of Angiographic and Ultrasound Assessment of Plaque Progression to Clinical Outcomes
|
Weintraub, William S.
|
|
1998
|
81 |
8S1 |
p. 69F-72F
nvt p.
|
artikel
|
| 30 |
Requirements and Methods for Documenting Diet Uniformity and Compliance in Drug Development Trials
|
Held, Jolene
|
|
1998
|
81 |
8S1 |
p. 31F-33F
nvt p.
|
artikel
|
| 31 |
Requirements for Claims of Favorable Effects on Serum Lipids by Oral Antidiabetic Agents
|
Carmena, Rafael
|
|
1998
|
81 |
8S1 |
p. 56F-57F
nvt p.
|
artikel
|
| 32 |
The Challenge of Regulating Development and Approval of Drugs with Pleiotropic Action in Cardiovascular Disease
|
Temple, Robert
|
|
1998
|
81 |
8S1 |
p. 5F-9F
nvt p.
|
artikel
|
| 33 |
The Role of the Central Clinical Laboratory in the Development of Drugs for the Treatment of Cardiovascular Disease by the Modification of Lipoprotein Concentrations
|
Cole, Thomas G
|
|
1998
|
81 |
8S1 |
p. 75F-77F
nvt p.
|
artikel
|
| 34 |
Update on the U.S. Food and Drug Administration Regulatory Approach to Over-the-Counter Cholesterol-Lowering Drugs
|
Orloff, David G
|
|
1998
|
81 |
8S1 |
p. 79F-
1 p.
|
artikel
|
| 35 |
Use of Apolipoprotein Parameters and Endpoints in Drug Development and Approval Processes
|
Alaupovic, Petar
|
|
1998
|
81 |
8S1 |
p. 40F-47F
nvt p.
|
artikel
|
Tijdschrift beschrijving